| Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non–cystic fibrosis bronchiectasis: the BAT randomized controlled trial J Altenburg, CS de Graaff, Y Stienstra, JH Sloos, EHJ van Haren, ... Jama 309 (12), 1251-1259, 2013 | 591 | 2013 |
| Immunomodulatory effects of macrolide antibiotics–part 1: biological mechanisms J Altenburg, CS De Graaff, TS Van Der Werf, WG Boersma Respiration 81 (1), 67-74, 2010 | 212 | 2010 |
| Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis JD Chalmers, W Boersma, M Lonergan, L Jayaram, ML Crichton, ... The lancet Respiratory medicine 7 (10), 845-854, 2019 | 123 | 2019 |
| Immunomodulatory effects of macrolide antibiotics–part 2: advantages and disadvantages of long-term, low-dose macrolide therapy J Altenburg, CS De Graaff, TS Van der Werf, WG Boersma Respiration 81 (1), 75-87, 2010 | 115 | 2010 |
| Multinational observational cohort study of COVID-19–associated pulmonary aspergillosis NAF Janssen, R Nyga, L Vanderbeke, C Jacobs, M Ergün, JB Buil, ... Emerging infectious diseases 27 (11), 2892, 2021 | 102 | 2021 |
| Seizure detection in the neonatal EEG with synchronization likelihood J Altenburg, RJ Vermeulen, RLM Strijers, WPF Fetter, CJ Stam Clinical neurophysiology 114 (1), 50-55, 2003 | 99 | 2003 |
| Rituximab in life threatening antisynthetase syndrome E Vandenbroucke, JC Grutters, J Altenburg, WG Boersma, EJ Ter Borg, ... Rheumatology international 29, 1499-1502, 2009 | 95 | 2009 |
| Rheumatoid arthritis–associated autoantibodies in non–rheumatoid arthritis patients with mucosal inflammation: a case–control study KMJ Janssen, MJ de Smit, E Brouwer, FAC de Kok, J Kraan, J Altenburg, ... Arthritis research & therapy 17, 1-10, 2015 | 93 | 2015 |
| Characterization of eosinophilic bronchiectasis: a European multicohort study A Shoemark, M Shteinberg, A De Soyza, CS Haworth, H Richardson, ... American journal of respiratory and critical care medicine 205 (8), 894-902, 2022 | 86 | 2022 |
| Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch Teaching Hospital J Altenburg, K Wortel, TS Van der Werf, WG Boersma Neth J Med 73 (4), 147-54, 2015 | 59 | 2015 |
| Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC) JD Chalmers, E Polverino, ML Crichton, FC Ringshausen, A De Soyza, ... The Lancet Respiratory Medicine 11 (7), 637-649, 2023 | 45 | 2023 |
| The European multicentre bronchiectasis audit and research collaboration (EMBARC) ERS clinical research collaboration S Aliberti, E Polverino, JD Chalmers, J Altenburg, M Shteinberg, ... European Respiratory Journal 52 (5), 2018 | 31 | 2018 |
| Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients AH Neerincx, K Whiteson, JL Phan, P Brinkman, MI Abdel-Aziz, ... ERJ open research 7 (2), 2021 | 29 | 2021 |
| Validation of a visual analogue score (LRTI‐VAS) in non‐CF bronchiectasis J Altenburg, K Wortel, CS de Graaff, TS van der Werf, WG Boersma The Clinical Respiratory Journal 10 (2), 168-175, 2016 | 27 | 2016 |
| Heterogeneity of treatment response in bronchiectasis clinical trials O Sibila, E Laserna, A Shoemark, L Perea, D Bilton, ML Crichton, ... European Respiratory Journal 59 (5), 2022 | 23 | 2022 |
| Nasal nitric oxide measurement and a modified PICADAR score for the screening of primary ciliary dyskinesia in adults with bronchiectasis J Rademacher, A Buck, N Schwerk, M Price, J Fuge, T Welte, ... Pneumologie 71 (08), 543-548, 2017 | 22 | 2017 |
| Aetiology and disease severity are among the determinants of quality of life in bronchiectasis LC Terpstra, S Biesenbeek, J Altenburg, WG Boersma The clinical respiratory journal 13 (8), 521-529, 2019 | 21 | 2019 |
| Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis T Lee, GS Sawicki, J Altenburg, SJ Millar, JM Geiger, MT Jennings, Y Lou, ... Journal of Cystic Fibrosis 22 (3), 402-406, 2023 | 17 | 2023 |
| Safety and outcomes of amikacin Liposome inhalation suspension for Mycobacterium Abscessus pulmonary disease: a NTM-NET study SMH Zweijpfenning, R Chiron, S Essink, J Schildkraut, OW Akkerman, ... Chest 162 (1), 76-81, 2022 | 17 | 2022 |
| Bronchiectasis in severe asthma: does it make a difference? SA Bendien, S van Loon-Kooij, G Kramer, W Huijgen, J Altenburg, ... Respiration 99 (12), 1136-1144, 2021 | 16 | 2021 |
